Literature DB >> 11006180

Prediction models for insulin resistance in the polycystic ovary syndrome.

G Gennarelli1, J Holte, L Berglund, C Berne, M Massobrio, H Lithell.   

Abstract

Women with the polycystic ovary syndrome (PCOS) have a high prevalence of insulin resistance, with consequent increased risk of metabolic diseases later in life. An early metabolic screening would therefore be of clinical relevance. By using stepwise regression analysis on several variables obtained in 72 women with PCOS, we constructed simple and reliable mathematical models predicting insulin sensitivity, as measured by the euglycaemic hyperinsulinaemic clamp. The normal ranges of insulin sensitivity were calculated from 81 non-hirsute, normally menstruating women with normal ovaries, and similar body mass index (BMI) and age as the women with PCOS. Measured variables included BMI, waist and hip circumferences, truncal-abdominal skin folds, circulating concentrations of gonadotrophins, androgens, sex hormone-binding globulin (SHBG), triglycerides, total cholesterol and cholesterol subfractions, fasting insulin, C-peptide and free fatty acids. The three best prediction models included waist circumference, together with insulin (model I: R(2) = 0.77), serum triglycerides (model II: R(2) = 0.65), and the subscapularis skin fold (model III: R(2) = 0. 64). Using reference limits for insulin sensitivity obtained in the 81 normal pre-menopausal women, the models identify insulin resistant women with PCOS. These simple and inexpensive models are potentially useful in clinical practice as an early screening in women with PCOS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11006180     DOI: 10.1093/humrep/15.10.2098

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  7 in total

1.  Reproductive endocrinology: Infertility treatment in PCOS--is metformin in from the cold?

Authors:  Evanthia Diamanti-Kandarakis
Journal:  Nat Rev Endocrinol       Date:  2012-05-01       Impact factor: 43.330

2.  Role of metformin in the management of polycystic ovary syndrome.

Authors:  Hany Lashen
Journal:  Ther Adv Endocrinol Metab       Date:  2010-06       Impact factor: 3.565

3.  Fasting glucose to leptin ratio as a new diagnostic marker in patients with diabetes mellitus.

Authors:  Rayah S Baban; Khawla A K Kasar; Isam N Al-Karawi
Journal:  Oman Med J       Date:  2010-10

4.  Body composition, fat distribution and metabolic characteristics in lean and obese women with polycystic ovary syndrome.

Authors:  E Faloia; P Canibus; C Gatti; F Frezza; M Santangelo; G G M Garrapa; M Boscaro
Journal:  J Endocrinol Invest       Date:  2004-05       Impact factor: 4.256

5.  No difference in markers of adipose tissue inflammation between overweight women with polycystic ovary syndrome and weight-matched controls.

Authors:  Asa Lindholm; Caroline Blomquist; Marie Bixo; Ingrid Dahlbom; Tony Hansson; Inger Sundström Poromaa; Jonas Burén
Journal:  Hum Reprod       Date:  2011-04-08       Impact factor: 6.918

6.  High plasma homocysteine and insulin resistance in patients with polycystic ovarian syndrome.

Authors:  Tayebe Hemati; Nasrin Moghadami-Tabrizi; Fateme Davari-Tanha; Bahram Salmanian; Pouya Javadian
Journal:  Iran J Reprod Med       Date:  2011

7.  Insulin dynamics in young women with polycystic ovary syndrome and normal glucose tolerance across categories of body mass index.

Authors:  Melania Manco; Lidia Castagneto-Gissey; Eugenio Arrighi; Annamaria Carnicelli; Claudia Brufani; Rosa Luciano; Geltrude Mingrone
Journal:  PLoS One       Date:  2014-04-04       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.